ACADIA Pharmaceuticals Q4 2023 GAAP EPS $0.28 Misses $0.31 Estimate, Sales $231.04M Beat $223.79M Estimate
Portfolio Pulse from Benzinga Newsdesk
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported Q4 2023 earnings of $0.28 per share, missing the consensus estimate of $0.31. However, their quarterly sales of $231.04 million exceeded the estimate of $223.79 million, marking a 69.27% increase from the previous year.

February 27, 2024 | 9:13 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
ACADIA Pharmaceuticals reported lower-than-expected Q4 2023 EPS but exceeded sales forecasts, showing significant year-over-year growth.
The miss in EPS might initially disappoint investors, potentially putting downward pressure on ACAD's stock price. However, the significant beat on sales forecasts and the impressive year-over-year growth could counterbalance the negative impact, leading to a neutral short-term price direction. Investors might focus on the strong sales performance as a positive indicator of the company's growth trajectory.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100